Conventional topical treatment of atopic dermatitis

Atopic Dermatitis

Volumn , Issue , 2002, Pages 453-477

  Boguniewicz, Mark ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052119487     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (104)

1. Broberg A, Kalimo K, Lindblad B, Swanbeck G. Parental education in the treatment of childhood atopic eczema. Acta Derm Venereol 1990; 70(6):495-499.
2. Nassif A, Chan SC, Storrs FJ, Hanifin JM. Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch Dermatol 1994; 130(11):1402-1407.
3. Tabata N, Tagami H, Kligman AM. A twenty-four-hour occlusive exposure to 1% sodium lauryl sulfate induces a unique histopathologic inflammatory response in the xerotic skin of atopic dermatitis patients. Acta Derm Venereol (Stockh) 1998; 78:244-247.
4. Forsch PJ, Kligman AM. The soap chamber test, a new method for assessing the irritancy of soaps. J Am Acad Dermatol 1979; 1:35-41.
5. Breneman DL, Hanifin JM, Berge CA, Keswick BH, Neumann PB. The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis 2000; 66(4):296-300.
6. Langeveld-Wildschut EG, Reidl H, Thepen T, et al. Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. J Allergy Clin Immunol 2000; 105:1008-1016.
7. Fischer B, Yawalkar N, Brander KA, Pichler WJ, Helbling A. Coprinus comatus (shaggy cap) is a potential source of aeroallergen that may provoke atopic dermatitis. J Allergy Clin Immunol 1999; 104:836-841.
8. Scalabrin DM, Bavbek S, Perzanowski MS, Wilson BB, Platts-Mills TA, Wheatley LM. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 1999; 104:1273-1279.
9. Schafer T, Heinrich J, Wjst M, Adam Heinrich, Ring J, Wichmann H-E. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 1999; 104:1280-1284.
10. van Reijsen FC, Bruijnzeel-Koomen CA, Kalthoff FS, Maggi E, Romagnani S, Westland JK, et al. Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992; 90:184-193.
11. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of house dust-mite allergen avoidance on atopic dermatitis. Lancet 1996; 347:15-18.
12. Holm L, Ohman S, Bengtsson A, van Hage-Hamsten M, Scheynius A. Effectiveness of occlusive bedding in the treatment of atopic dermatitis—a placebocontrolled trial of 12 months’ duration. Allergy 2001; 56:152-158.
13. Wood RA, et al. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med 1998; 158:115-120.
14. Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol (Stockh) 1985; 65: 102-105.
15. Werner Y. The water content of the stratum corneum in patients with atopic dermatitis. Acta Derm Venereol (Stockh) 1986; 66:281-284.
16. Fartasch M, Diepgen T. The barrier function in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids? Acta Derm Venereol Suppl (Stockh) 1992; 176:26-31.
17. Linde Y. Dry skin in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 177:9-13.
18. Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 1991; 96:523-526.
19. Kubota K, Machida I, Tamura K, et al. Treatment of refractory cases of atopic dermatitis with acidic hot-spring bathing. Acta Derm Venereol 1997; 77:452-454.
20. Inoue T, Inoue S, Kubota K. Bactericidal activity of manganese and iodide ions against Staphylococcus aureus: a possible treatment for acute atopic dermatitis. Acta Derm Venereol 1999; 79:360-362.
21. Loden M. Biophysical properties of dry atopic and normal skin with special reference to effects of skin care products. Acta Derm Venereol Suppl (Stockh) 1995; 192:1-48.
22. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroidsparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997; 14(4):321-324.
23. Tabata N, O’Goshi K, Zhen YX, Kligman AM, Tagami H. Biophysical assessment of persistent effects of moisturizers after their daily applications: evaluation of cor-neotherapy. Dermatology 2000; 200(4):308-313.
24. Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Cano-derm). Br J Dermatol 1999; 140(2):264-267.
25. Hagstromer L, Nyren M, Emtestam L. Do urea and sodium chloride together increase the efficacy of moisturisers for atopic dermatitis skin? A comparative, double-blind and randomised study. Skin Pharmacol Appl Skin Physiol 2001; 14(1):27-33.
26. Vilaplana J, Coll J, Trullas C, Azon A, Pelejero C. Clinical and non-invasive evaluation of 12% ammonium lactate emulsion for the treatment of dry skin in atopic and non-atopic subjects. Acta Derm Venereol 1992; 72(1):28-33.
27. Lavker RM, Kaidbey K, Leyden J. Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid. J Am Acad Dermatol 1992; 26: 535-544.
28. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998; 78(1): 27-30.
29. Bleck O, Abeck D, Ring J, Hoppe U, Vietzke JP, Wolber R, Brandt O, Schreiner V. Two ceramide subfractions detectable in Cer(AS) position by HPTLC in skin surface lipids of non-lesional skin of atopic eczema. J Invest Dermatol 1999; 113(6):894-900.
30. Hara J, Higuchi K, Okamoto R, Kawashima M, Imokawa G. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 2000; 115(3):406-413.
31. Man MQ M, Feingold KR, Thornfeldt CR, Elias PM. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996; 106(5):1096-1101.
32. Barnes PJ. New directions in allergic diseases: mechanism-based anti-inflammatory therapies. J Allergy Clin Immunol 2000; 106(1 Pt 1):5-16.
33. Yawalkar N, Karlen S, Egli F, Brand CU, Graber HU, Pichler WJ, Braathen LR. Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitis. J Allergy Clin Immunol 2000; 106(5):941-947.
34. Stoughton RB. Vasoconstrictor assay-specific applications. In: Maibach HI, Surber C, eds. Topical Corticosteroids. Basel: Karger, 1992:42-53.
35. Stoughton RB. The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments. Int J Dermatol 1992; 31:26-28.
36. Volden G. Successful treatment of therapy-resistant atopic dermatitis with clobeta-sol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol Suppl (Stockh) 1992; 176:126-128.
37. Vernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991; 24:603-607.
38. Kligman AM, Frosch PJ. Steroid addiction. J Int J Dermatol 1979; 18:23-31.
39. Rapaport MJ Rapaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J Am Acad Dermatol 1999; 41(3 Pt 1):435-442.
40. McLean C, Lobo R, Brazier D. Cataracts, glaucoma, femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 1995; 345:3330.
41. Dooms-Goossens A, Morren M. Results of routine patch testing with corticosteroid series in 2073 patients. Contact Dermatitis 1992; 26:182-191.
42. Matura M, Goossens A. Contact allergy to corticosteroids. Allergy 2000; 55:698-704.
43. Seukeran DC, et al. Patch testing to detect corticosteroid allergy: Is it adequate? Contact Dermatitis 1997; 36:127-130.
44. Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol 1998; 138(2):293-296.
45. Wolkerstorfer A, et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998; 39:226-231.
46. Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol 1999; 38(8):604-606.
47. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999; 140:1114-1121.
48. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992; 27:29-34.
49. Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994; 131:536-540.
50. Clayton MH, Leung DYM, Surs W, Szefler SJ. Altered glucocorticoid binding in atopic dermatitis. J Allergy Clin Immunol 1995; 96:421-423.
51. Herrscher RF, Kasper C, Sullivan TJ. Endogenous cortisol regulates immunoglobulin E-dependent late phase reaction. J Clin Invest 1992; 90:596-603.
52. Blotta MH, DeKruyff RH, Umetsu DT. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 1997; 158:5589-5595.
53. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142:931-936.
54. Langeveld-Wildschut EG, et al. Modulation of the atopy patch test reaction by topical corticosteroids and tar. J Allergy Clin Immunol 2000; 106:737-43.
55. Wolkerstorfer A, et al. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. Br J Dermatol 2000; 143:999-1004.
56. Nicol NH. Atopic dermatitis: the (wet) wrap-up. Am J Nurs 1987; 87(12):1560-1563.
57. Leyden JE, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974; 90:525-530.
58. Leyden J, Kligman A. The case for steroid-antibiotic combinations. Br J Dermatol 1977; 96:179-187.
59. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119: 189-198.
60. Abeck D, Mempel M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998; 139(suppl 53):13-16.
61. Albert MR, Gonzalez S, Gonzalez E. Patch testing reactions to a standard series in 608 patients tested from 1990 to 1997 at Massachusetts General Hospital. Am J Contact Dermat 1998; 9(4):207-211.
62. Williams JV, et al. Saureus isolation from the lesions, the hands, and the anterior nares of patients with atopic dermatitis. Ped Dermatol 1998; 15:194-198.
63. Doebeling BN, et al. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994; 154:1505-1508.
64. Luber H, Amornsiripanitch S, Lucky AW. Mupirocin and the eradication of Staphylococcus aureus in atopic dermatitis. Arch Dermatol 1988; 124:853-854.
65. 4) on bacterial skin flora in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 176:132-134.
66. Brockow K, Grabenhorst P, Abeck D, Traupe B, Ring J, Hoppe U, Wolf F. Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus aureus-colo-nized atopic eczema. Dermatology 1999; 199(3):231-236.
67. Akiyama H, Tada J, Toi J, Kanzaki H, Arata J. Changes in Staphylococcus aureus density and lesion severity after topical application of povidone-iodine in cases of atopic dermatitis. J Dermatol Sci 1997; 16(1):23-30.
68. Jensen-Jarolim E, Poulsen L, With H, Kieffer M, Ottevanger V, Skov P. Atopic dermatitis of the face, scalp and neck: type I reaction to the yeast Pityrosporum ovale? J Allergy Clin Immunol 1992; 89:44-51.
69. Back O, Scheynius A, Johansson SG. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res 1995; 287: 448-451.
70. Nissen D. et al. IgE-sensitization to cellular and culture filtrates of fungal extracts in patients with atopic dermatitis. Ann Allergy Asthma Immunol 1998; 81:247-255.
71. Wahlgren CF. Itch and atopic dermatitis: an overview. J Dermatol 1999; 26(11): 770-779.
72. Drake LA, Fallon JD, Sober A, Group DS. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol 1994; 31(4):613-616.
73. Drake LA, Cohen L, Gillies R, Flood JG, Riordan AT, Phillips SB, Stiller MJ. Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. J Am Acad Dermatol 1999; 41(2 Pt 1):209-214.
74. Groene D, Martus P, Heyer G. Doxepin affects acetylcholine induced cutaneous reactions in atopic eczema. Exp Dermatol 2001; 10(2):110-117.
75. Sabroe RA, Kennedy CT, Archer CB. The effects of topical doxepin on responses to histamine, substance P and prostaglandin E2 in human skin. Br J Dermatol 1997; 137(3):386-390.
76. Weisshaar E, Heyer G, Forster C, Handwerker HO. Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. Arch Dermatol Res 1998; 290(6):306-311.
77. Rukwied R, et al. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 2000; 142:1114-1120.
78. Nilsson H-J, Levinsson A, Schouenborg, J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain 1997; 71:49-55.
79. Cooper KD, Kang K, Chan SC, Hanifin JM. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 1985; 84:477-482.
80. Butler JM, Chan SC, Stevens S, Hanifin JM. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol 1983; 71:490-497.
81. Hanifin JM, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107:51-56.
82. Essayan DM, Huang S, Kagey-Sobotka A, et al. Differential efficacy of lymphocyte- and monocyte- selective pretreatment with a Type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J Allergy Clin Immunol 1997; 99:28-37.
83. Santamaria LF, et al. Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes. J Invest Dermatol 1999; 113:82-86.
84. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66:807-815.
85. De Rie MA, Meinardi MHM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991; 71(5):452-454.
86. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DYM, Hanifin JM, Pediatric Tacrolimus Study Group. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102:637-644.
87. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S, European Tacrolimus Multicenter Atopic Dermatitis Study Group. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337(12):816-821.
88. Hanifin JM. Tacrolimus ointment: Advancing the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44(1 suppl):S1-S72.
89. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134(7):805-809.
90. Burek-Kozlowska A, Morell A, Hunziker T. Topical immunoglobulin G in atopic dermatitis. Int Arch Allergy Immunol 1994; 104(1):104-106.
91. Gollner GP, Muller G, Alt R, Knop J, Enk AH. Therapeutic application of T cell receptor mimic peptides or cDNA in the treatment of T cell-mediated skin diseases. Gene Ther 2000; 7(12):1000-1004.
92. Yoshizawa Y, Matsui H, Izaki S, Kitamura K, Maibach HI. Topical dinitrochloro-benzene therapy in the treatment of refractory atopic dermatitis: systemic immunotherapy. J Am Acad Dermatol 2000; 42(2 Pt 1):258-262.
93. Mills LB, Mordan LJ, Roth HL, Winger EE, Epstein WL. Treatment of severe atopic dermatitis by topical immune modulation using dinitrochlorobenzene. J Am Acad Dermatol 2000; 42(4):687-689.
94. Ernst E. Adverse effects of herbal drugs in dermatology. Br J Dermatol 2000; 143(5):923-929.
95. Wood B, Wishart J. Potent topical steroid in a Chinese herbal cream. NZ Med J 1997; 110:420-421.
96. Allen BR, Parkinson R. Chinese herbs for eczema. Lancet 1990; 336:177.
97. Keane FM, Munn SE, du Vivier AWP, et al. Analysis of Chinese herbal creams prescribed for dermatological conditions. Br Med J 1999; 318:563-567.
98. Watanabe T, Kuroda Y. The effect of a newly developed ointment containing eico-sapentaenoic acid and docosahexaenoic acid in the treatment of atopic dermatitis. J Med Invest 1999; 46(3-4):173-177.
99. Gehring W, Bopp R, Rippke F, Gloor M. Effect of topically applied evening primrose oil on epidermal barrier function in atopic dermatitis as a function of vehicle. Arzneimittelforschung 1999; 49(7):635-642.
100. Berth-Jones J, Graham-Brown RA. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. Lancet 1993; 341(8860):1557-1560.
101. Patzelt-Wenczler R, Ponce-Poschl E. Proof of efficacy of Kamillosan(R) cream in atopic eczema. Eur J Med Res 2000; 5(4):171-175.
102. Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol 2000; 143(3):524-531.
103. Moore C, Ehlayel MS, Junprasert J, Sorensen RU. Topical sodium cromoglycate in the treatment of moderate-to-severe atopic dermatitis. Ann Allergy Asthma Immunol 1998; 81(5 Pt 1):452-458.
104. Schachner L, Field T, Hernandez-Reif M, Duarte AM, Krasnegor J. Atopic dermatitis symptoms decreased in children following massage therapy. Pediatr Dermatol 1998; 15(5):390-395.